Thiogenesis Therapeutics, Corp.
TTIPF
$0.44
$0.02897.03%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 200.10K | 192.30K | 209.10K | 248.60K | 172.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 496.90K | 534.70K | 632.90K | 1.56M | 816.60K |
| Operating Income | -496.90K | -534.70K | -632.90K | -1.56M | -816.60K |
| Income Before Tax | -481.60K | -476.00K | -527.00K | -1.52M | -786.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -481.60K | -476.00K | -527.00K | -1.52M | -786.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -481.60K | -476.00K | -527.00K | -1.52M | -786.20K |
| EBIT | -496.90K | -534.70K | -632.90K | -1.56M | -816.60K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.04 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 45.50M | 45.50M | 44.69M | 39.93M | 38.86M |
| Average Diluted Shares Outstanding | 45.50M | 45.50M | 44.69M | 39.93M | 38.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |